The stock of Omeros Corporation (NASDAQ:OMER) is a huge mover today! About 865,150 shares traded hands. Omeros Corporation (NASDAQ:OMER) has declined 11.56% since April 13, 2016 and is downtrending. It has underperformed by 15.49% the S&P500.
The move comes after 7 months positive chart setup for the $625.60 million company. It was reported on Nov, 15 by Barchart.com. We have $17.26 PT which if reached, will make NASDAQ:OMER worth $162.66M more.
Omeros Corporation (NASDAQ:OMER) Ratings Coverage
Out of 6 analysts covering Omeros (NASDAQ:OMER), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Omeros has been the topic of 11 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Roth Capital on Monday, August 10. The company was maintained on Monday, August 31 by Needham. The firm earned “Buy” rating on Friday, June 3 by Cantor Fitzgerald. The firm earned “Outperform” rating on Tuesday, August 18 by Cowen & Co. The rating was maintained by WBB Securities on Tuesday, August 18 with “Strong Buy”. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by TH Capital on Monday, August 10. Needham maintained Omeros Corporation (NASDAQ:OMER) rating on Thursday, November 10. Needham has “Buy” rating and $24 price target. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by Needham on Wednesday, November 11.
According to Zacks Investment Research, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.”
Insitutional Activity: The institutional sentiment decreased to 0.77 in 2016 Q2. Its down 0.21, from 0.98 in 2016Q1. The ratio is negative, as 15 funds sold all Omeros Corporation shares owned while 32 reduced positions. 13 funds bought stakes while 23 increased positions. They now own 19.91 million shares or 14.90% more from 17.33 million shares in 2016Q1.
Blackrock Limited Liability Corporation, a Delaware-based fund reported 17,415 shares. Barclays Public Ltd Llc holds 0% or 531 shares in its portfolio. Grp Incorporated One Trading Ltd Partnership holds 0% or 8,161 shares in its portfolio. Gsa Prtn Llp has 0.04% invested in the company for 72,400 shares. D E Shaw And has 0.01% invested in the company for 370,385 shares. Alliancebernstein L P, a New York-based fund reported 54,000 shares. Invesco Limited reported 80,525 shares or 0% of all its holdings. Blackrock Ltd Company last reported 154,233 shares in the company. Davenport & Ltd Liability Com owns 59,200 shares or 0% of their US portfolio. Chicago Equity Prns Limited has 0.03% invested in the company for 91,325 shares. Ingalls Snyder Ltd Llc holds 4.41 million shares or 2.74% of its portfolio. Rtw Ltd Com holds 1.89% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 526,788 shares. Credit Suisse Ag holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 49,410 shares. Ladenburg Thalmann Fincl Services accumulated 1,770 shares or 0% of the stock. Teachers Advsr Inc accumulated 0% or 57,987 shares.
Insider Transactions: Since May 16, 2016, the stock had 0 insider purchases, and 4 sales for $574,464 net activity. On Thursday, September 15 Kelbon Marcia S. sold $174,578 worth of the stock or 16,000 shares. 3,000 shares were sold by Cable Thomas J., worth $34,557.
More recent Omeros Corporation (NASDAQ:OMER) news were published by: Fool.com which released: “Why Omeros Corporation Is Soaring 17.7% Today” on November 10, 2016. Also Businesswire.com published the news titled: “Omeros Corporation to Announce Third Quarter 2016 Financial Results on …” on November 07, 2016. Seekingalpha.com‘s news article titled: “Encouraging News From Omeros Corporation” with publication date: October 18, 2016 was also an interesting one.
OMER Company Profile
Omeros Corporation, incorporated on June 16, 1994, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is launched in the United States for use during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from the Company’s PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. The Company’s PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.